|
Bulk APIs |
|
Valsartan [137862-53-4] (USP) |
Homatropine Methylbromide [80-49-9 ] (EP, BP, USP) |
|
Homatropine Hydrobromide [51-56-9 ] (EP, BP, USP) |
Ketorolac Tromethamine [74103-07-4] (EP, BP, USP) |
|
Tramadol Hydrochloride [36282-47-0 ] ( EP, BP) |
Sertraline Hydrochloride [79559-97-0 ] (EP) (Contract manufacturing) |
|
Venlafaxine Hydrochloride [99300-78-4] (EP, BP) (Contract
manufacturing) |
Ofloxacin [82419-36-1] (EP, USP, BP) (Contract manufacturing) |
|
Levofloxacin Hemihydrate [100986-85-4] (IHS) |
Metformin Hydrochloride [1115-70-4] (IP, EP, BP, USP) |
|
Clopidogrel Bisulfate, Form II [120202-66-6] (USP) |
Rabeprazole Sodium [117976-90-6] (IP & IHS) |
|
Amiodarone Hydrochloride [19774-82-4] (IP, EP, BP, USP) |
|
|
Under Development |
|
Donepezil Hydrochloride [120011-70-3] (IHS) |
Solifenacin Succinate [242478-38-2] (IHS) |
|
Darifenacine [133099-04-4] (IHS) |
Disodium Cromoglicate [15826-37-6] (IP, EP, BP) |
|
Pantoprazole Sodium Sesquihydrate [138786-67-1] (EP) |
Telmesartan [485391-74-0] (IHS) |
|
Candesartan cilexetil [145040-37-5] (IHS) |
Pentoxifylline [6493-05-6] (IHS) |
|
Advanced Intermediates |
|
Valsartan
5-(4-Bromomethyl-1,1’-biphenyl-2-yl)-1-triphenylmethyl-1h-tetrazole
[124750-51-2]
L-Valine Benzyl Ester Hydrochloride [2462-34-2]
L-Valine Benzyl Ester P-Toluene Sulphonate [16652-76-9]
5-(2-Bromophenyl)-n-(triphenylmethyl)-tetrazole [143945-72-6] |
Lisinopril
L-Proline benzyl ester hydrochloride [16652-71-4]
2-Phenylethyl chloride [622-24-2]
Isopropyl Trifluoroacetate [400-38-4] |
|
Ketorolac Tromethamine
Benzoyl morpholine [1468-28-6]
Ketorolac [74103-06-3] |
|
|
Cephalosporin and Carbapenem Intermediates: |
|
Mica Ester [246035-38-1] |
4-Nitrobenzyl Bromide [100-11-8] |
|
4-Nitro Benzyl Alcohol [619-73-8] |
4-Nitrobenzyl Diazoacetoacetate [82551-63-1] |
|
1-Acetoxyethyl Bromide [40258-78-4] |
(z)-4-Bromo-2-methoxyimino-3-oxobutyric acid [79232-66-9] [Bromo
Acid] |
|
(z)-4-Chloro-2-methoxyimino-3-oxobutyric acid [111230-59-2] [Chloro
Acid] |
|
|
Other Intermediates |
|
5-Chloro Salicylamide [7120-43-6] |
4-Nitrobenzaldehyde [555-16-8] |
|
Benzyl Chloroacetate [140-18-1] |
2-Phenylacetamide [103-81-1] |
|
Under Development |
|
Triphenyl Phosphine Hydrobromide [6399-81-1] |
DL-Mandelic Acid [611-72-3 ] |
|
MAEM [84994-24-1] – For Cefotaxime, Ceftriaxone, Cefepime,
Ceftiofur, Cefpirome |
ATMA [65872-41-5] - For Cefotaxime, Ceftriaxone, Cefepime,
Ceftiofur, Cefpirome |
| |
|
|
Products protected by valid patents are not offered
for sale in countries where the sale of such
products constitutes a patent infringement and its
liability is at buyer's risk |
